Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 17/20 | 0.52 |
| ▸ | CA9 | Q16790 | 7/20 | 0.52 |
| ▸ | CA1 | P00915 | 16/20 | 0.51 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28698992 | 0.88 | CA1 (0.56) | CA2CA9CA1CA12CA6 | |
| SCHEMBL17019200 | 0.82 | GAA (0.49) | CA2CA9CA1CA12CA7 | |
| SCHEMBL7481802 | 0.81 | CA1 (0.61) | CA2CA9CA1CA12CA6 | |
| SCHEMBL6037565 | 0.79 | KMT2A (0.59) | — | |
| SCHEMBL17019196 | 0.78 | TDP1 (0.46) | CA2CA9CA1CA12CA5A | |
| SCHEMBL3206476 | 0.75 | KMT2A (0.50) | — | |
| SCHEMBL3195371 | 0.74 | ALDH1A1 (0.49) | — | |
| SCHEMBL31309573 | 0.74 | CA1 (0.70) | CA2CA9CA1CA12CA6 | |
| SCHEMBL4463532 | 0.74 | CA1 (0.70) | CA2CA9CA1CA12CA6 | |
| SCHEMBL6118940 | 0.73 | CA1 (0.69) | CA2CA9CA1CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783513-B2 | STAT3 inhibitors and their anticancer use | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150232434-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | OHIO STATE INNOVATION FOUNDATION | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232434-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | STAT3, STAT1, JAK1 | CA2 815/4885CA9 1141/4885CA1 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.